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Both genetic background and pre-existing stress play critical roles in the effects of antidepressant drugs.
The current studies showed this principal by demonstrating that exposure to the stress hormone
corticosterone (CORT) allowed behavioral and neurogenic effects to emerge following chronic treatment
with ﬂuoxetine of C57BL/6 mice, a strain ordinarily resistant to these effects. Adult male mice were
implanted subcutaneously with 21-day slow-release CORT pellets (10 mg) or placebo and then co-treated
with 5 mg/kg ﬂuoxetine (b.i.d., i.p.) or saline for 14 days. Animals were then assessed for approach
behavior in the novelty-induced hypophagia (NIH) test, hippocampal cell proliferation, corticosteroid
receptor expression, and CORT plasma levels. Co-treatment of CORT with ﬂuoxetine signiﬁcantly reduced
approach behavior in the novel environment of the NIH test and increased hippocampal cell proliferation
whereas ﬂuoxetine given alone was ineffective. CORT given alone did not alter approach behavior in the
novel environment and caused a smaller increase of cell proliferation. The CORT effect was blocked by
adrenalectomy and was likely due to increased adrenal feedback. Cell proliferation in CORT-treated
animals was associated with reduced mineralocorticoid, but not glucocorticoid, receptor mRNA
expression. Although the pellets were advertised to release CORT for 21 days, plasma CORT levels were
increased at 1 day after implantation but were not sustained when measured at 7 days or longer in-
tervals. Nevertheless, the transient CORT increase was sufﬁcient to induce long-lasting behavioral and
molecular changes when followed by ﬂuoxetine treatment. These studies warrant further investigation
into the role of glucocorticoids and environmental stress as adjunctive facilitators of the response to
antidepressants, especially for treatment-resistant patients.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Major Depressive Disorder (MDD) is one of the most common
psychiatric disorders, with a lifetime prevalence of 17% in the
United States and 4% worldwide (Eaton et al., 2008; Kessler et al.,
2005). In terms of years lost to disability, MDD is considered one
of the most disabling medical conditions and is predicted to
become a leading contributor to the worldwide burden of disease
(Mathers and Loncar, 2006). The majority of pharmacotherapies
developed for the treatment of MDD target brain monoamine
systems, primarily serotonin (5-HT), norepinephrine, anda, Department of Psychiatry,
, Room 2204, Philadelphia, PA
ki).
Inc. This is an open access article udopamine. The most common of these, the selective serotonin re-
uptake inhibitors (SSRIs) and selective norepinephrine reuptake
inhibitors (SNRIs), comprise a large proportion of pharmaceutical
sales and are considered ﬁrst line treatments for MDD. Unfortu-
nately, an estimated 40% of patients fail to respond to these ther-
apies (Cipriani et al., 2009; Culpepper, 2010). Further insight into
the neurobiological mechanisms underlying antidepressant
response is needed for the development of more efﬁcacious anti-
depressant regimens.
The combination of genetic vulnerabilities and environmental
factors, such as stress, are thought to be signiﬁcant contributors to
the onset of depression in humans (Charney and Manji, 2004). The
likelihood of experiencing a depressive episode is greatly increased
following a stressful life event or after accumulation of chronic
minor stresses (Caspi et al., 2003; Harkness and Monroe, 2006).
Moreover, many patients suffering from depression exhibit signs of
dysfunctional hypothalamic-pituitary-adrenal (HPA) axis activity,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dexamethasone, an exogenous steroid that suppresses cortisol in
healthy individuals (Gillespie and Nemeroff, 2005; Pariante and
Miller, 2001). Interestingly, successful antidepressant treatment is
often associated with restored suppression of HPA axis response
(Schule, 2007). Together, these ﬁndings suggest a potential role of
stress hormones, such as cortisol (corticosterone (CORT) in ro-
dents), in the pathology and treatment of depression.
CORT produces its effects in the central nervous system via
activation of glucocorticoid (GR) and mineralocorticoid (MR) re-
ceptors. Though these receptors are ubiquitous throughout the
brain, they are highly abundant in the hippocampus, where they
provide crucial inhibitory feedback signals to the HPA axis
(Jacobson and Sapolsky, 1991; Sapolsky et al., 1984). A reduction or
absence of these inhibitory signals can promote hyperactivation of
the axis and augmented secretion of glucocorticoids (Anacker et al.,
2011; McEwen et al., 2012). In a healthy individual, elevated
corticosteroid activity helps facilitate the physiological and
behavioral adaptations required to appropriately respond to
stressors and reinstate homeostasis. However, prolonged exposure
to CORT can inhibit the proliferation and survival of adult-born
hippocampal neurons, which have been shown to play an impor-
tant role in the behavioral and neuroendocrine components of
stress responses in rodents (Gould and Tanapat, 1999; Snyder et al.,
2011). Conversely, chronic treatment of normal rodents with SSRIs,
such as ﬂuoxetine, increases hippocampal neurogenesis and neu-
rotrophins such as brain derived neurotrophic factor (BDNF)
(Duman and Monteggia, 2006; Krishnan and Nestler, 2008;
Schmidt and Duman, 2006). Increased hippocampal neurogenesis
is associated with behavioral indications of antidepressant efﬁcacy
in rodents, such as reduced hyponeophagia in the novelty-induced
hypophagia (NIH) test and performance in the forced swim test
(Dranovsky and Hen, 2006).
Not all strains of mice respond to the behavioral and neurogenic
effects of antidepressant treatments. For example, normal C57BL/6
mice are unresponsive to the behavioral effects of chronic ﬂuoxe-
tine treatment, measured in the NIH test, and do not exhibit
increased hippocampal cell proliferation (Balu et al., 2009a). Ro-
dent strains that are unresponsive to antidepressants could provide
information about treatment resistance. However, the effects of
antidepressants may be altered after exposure to stress. CORT is a
vital component of the central nervous system's stress response
circuitry. Although corticosteroids alone do not encompass all as-
pects of stress exposure (Belzung, 2014), previous studies have
shown that chronic CORT exposure can induce a depressive-like
motivational state in rodents that is similar to that produced by a
chronic mild stress paradigm (Gourley et al., 2008). Moreover, CORT
treatment alone is sufﬁcient to alter molecular targets that are
implicated in depression and antidepressant efﬁcacy, such as hip-
pocampal neurogenesis (Bilsland et al., 2006; Gourley and Taylor,
2009). In a small clinical study Dinan et al. (1997), found that 4-
day dexamethasone therapy signiﬁcantly enhanced antidepres-
sant response to SSRIs in treatment-resistant patients. Therefore,
we hypothesized that activation of stress circuitry might be
important to reveal the behavioral and neurogenic effects of the
SSRI ﬂuoxetine in C57BL/6 mice, a non-responsive mouse strain.
In the current study we investigated the effects of exposure to
commercial CORT pellets for 21 days in augmenting ﬂuoxetine's
behavioral and proliferative effects in C57BL/6 mice. The results of
this study showed that chronic ﬂuoxetine produced behavioral
effects in the NIH test only in mice exposed to CORT. Furthermore,
CORT administration with ﬂuoxetine co-treatment augmented
hippocampal cell proliferation, an effect potentially mediated by
alterations in hippocampal corticosteroid receptor expression.
Interestingly, analysis of plasma at the end of treatment revealed aparadoxical decrease in CORT levels in animals treated with the
pellets, suggesting that the CORT pellets did not work as advertised.
Adrenalectomized animals implanted with CORT pellets revealed a
sharp drop in CORT plasma levels by day 7 of treatment, indicating
that this method of CORT exposure produced transiently elevated,
but not sustained, CORT levels. Nevertheless, these experiments
revealed the important ﬁnding that CORT exposure potentiates the
behavioral and neurogenic effects of chronic ﬂuoxetine adminis-
tration in a mouse strain that is otherwise non-responsive to this
antidepressant treatment.
2. Materials and methods
2.1. Animals
Intact and adrenalectomized male C57BL/6J, 7e8 weeks old
upon arrival, were purchased from Jackson Laboratories (Bar Har-
bor, ME). Mice were housed in groups of 4 (except for those used in
the NIH test whom were housed in pairs) in polycarbonate cages
and maintained on a 12 h lightedark cycle (lights on at 0700 h) in a
temperature (22 C)- and humidity-controlled environment. Food
and water were available ad libitum. All experiments were
approved by the Institutional Animal Care and Use Committee at
the University of Pennsylvania.
2.2. Experimental design
2.2.1. Experiment 1
Intact animals were implanted with CORT pellets (10 mg) or
placebo pellets. Beginning on day 7 of CORT treatment, animals
were dosed with either ﬂuoxetine (5 mg/kg b.i.d., i.p.) or saline
daily for the remaining 14 days of the experiment. Cohort 1: Ani-
mals were tested in the NIH and home cage test on the last two days
of drug treatment (n¼ 8e10 per group). Cohort 2: Animals received
a single injection of BrdU on the last day of drug treatment and
were sacriﬁced 24 h later. In these animals hippocampal tissue was
dissected and analyzed for BrdU positive cells and corticosteroid
mRNA expression. Trunk blood was collected at time of sacriﬁce
and analyzed for plasma CORT levels (n ¼ 15e19 per group).
2.2.2. Experiment 2
Adrenalectomized animals were implanted with CORT pellets
(10 mg) or placebo pellets and received chronic ﬂuoxetine treat-
ment as described in Experiment 1. All mice received additional
CORT replacement through the drinking water (25 mg/ml in 0.9%
saline) to prevent the loss of electrolyte homeostasis (Funder, 2006)
and eliminate the confounding effects of adrenalectomy alone on
neurogenesis (Cameron and Gould,1994). Animals received a single
injection of BrdU on the last day of drug treatment and were
sacriﬁced 24 h later. Hippocampal tissue was dissected and
analyzed for BrdU positive cells (n ¼ 7e10 per group).
2.2.3. Experiment 3
Intact animals were implanted with CORT pellets (2.5 mg) or
placebo pellets and received chronic ﬂuoxetine treatment as
described in Experiment 1. Animals received a single injection of
BrdU on the last day of drug treatment and were sacriﬁced 24 h
later. Hippocampal tissue was dissected and analyzed for BrdU
positive cells (n ¼ 9e10 per group).
2.2.4. Experiment 4
Adrenalectomized animals were implanted with CORT pellets
(10 mg) or placebo pellets and then sacriﬁced 1, 7, 14, or 21 days
after implantation. Trunk blood was collected at time of sacriﬁce
and analyzed for plasma CORT levels (n ¼ 5e6 per group).
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CORT pellets (2.5 mg and 10 mg, 21 day release, Innovative
Research of America, Sarasota, FL, USA) were composed of a pro-
prietary matrix of cholesterol, cellulose, lactose, phosphates and
stearates designed to facilitate continuous and sustained diffusion
of CORT over a period of 21 days. Placebo pellets consisted of the
same matrix without the active product. Fluoxetine hydrochloride
(5 mg/kg; Anawa, Zurich) was dissolved in distilled water and
delivered by intraperitoneal (i.p.) injection in a volume of 10 ml/kg.
Fluoxetine was administered twice daily because, due to its half-
life, this dosing strategy results in relatively stable plasma levels
(Hodes et al., 2010) and occupation of brain serotonin transporters
(Hirano et al., 2004). Control animals received saline (0.9% NaCl). 5-
Bromo-deoxyuridine (BrdU; Roche Applied Sciences Indianapolis,
IN) was dissolved in warm saline at a dose of 200 mg/kg and
administered i.p. in a volume of 10 ml/kg.2.4. NIH test
Mice were pair housed and trained to eat a palatable food (three
peanut butter chips presented in a small, clear petri dish) in a home
cage environment. Animals were trained daily in 15-min sessions
until they met the criteria of three consecutive days with approach
latencies of 30 s or less. Opaque, black, plastic dividers were placed
inside each cage to separate the mice during training of home cage
training sessions. Micewere allowed to habituate to the dividers for
1 h before the start of the training session. Once all animals hadmet
criteria, training sessions were suspended and drug treatments
were initiated. Three days before novel testing all animals were re-
exposed to the peanut butter chips through additional training
sessions. For novel cage testing, peanut butter chips were presented
in the center of an empty, clear polycarbonate cage
(25.5  46  20 cm) with bright lighting (60 W light bulb) and
scented with lemon (20% Lemon Joy solution). Novel cage testing
was videotaped. Micewere placed into the test cage and the latency
to approach during the 15-min test session was measured. The
approach latency was deﬁned as the time to ingestion. There was
no food deprivation or habituation period prior to the novel cage
test. All behavioral testing took place during the light phase. The
home cage test was performed the day after the novel cage test.2.5. BrdU incorporation using ﬂow cytometry
Flow cytometry is a frequently usedmethod for analyzing newly
dividing cells in the hippocampus. This method has been previously
validated by our lab and others, and compared to results obtained
from immunostaining (Balu et al., 2009b; Bilsland et al., 2006;
Spoelgen et al., 2011). BrdU labeling was measured in cells dis-
playing the nuclear marker 7-aminoactinomycin D (7-AAD) by ﬂow
cytometry as previously described (Balu et al., 2009b). Brieﬂy, mice
were decapitated 24 h following BrdU injection, their brains quickly
removed, and the hippocampus dissected. Hippocampal tissue was
manually minced, digested using an enzymatic mixture (1 mg/ml
papain, Roche Applied Science; 0.1 M L-cysteine, SigmaeAldrich, St.
Louis, MO), and then mechanically triturated to form a single cell
suspension. Cells were ﬁxed, permeabilized, and stained using the
ﬂuorescein isothiocyanate (FITC) BrdU Flow Kit (BD Biosciences,
San Jose, CA). Data were collected on the same day using a BD FACS
Canto System (BD Biosciences) at the University of Pennsylvania
Flow Cytometry Core Facility. Background signals were controlled
for by collecting data from a BrdU-free control. All data were
analyzed using BD FACSDiva Software (BD Biosciences).2.6. Analysis of corticosteroid receptor expression using
quantitative real-time polymerase chain reaction (qRT-PCR)
RNA was extracted with Trizol reagent (Gibco BRL, Life Tech-
nologies, NY) and puriﬁed using the RNeasy Mini Kit (Qiagen,
Valencia, CA) following the manufactures' instructions. RNA con-
centrations were measured and 300 ng/ml RNA was used as a
template to synthesize c-DNA using the Superscript Vilo c-DNA
Synthesis kit (Invitrogen, Carlsbad, CA, USA). All reactions were
performed with a master mix of SYBR green (Applied Biosystems,
Austin, TX) and 300 nM primers (ﬁnal concentration). Quantitative
real-time polymerase chain reactions (qRT-PCR) were run using the
Stratagene MX3000 andMXPro QPCR software. Cycling parameters
were as follows: 95 C for 10 min, 40 cycles at 95 C (30 s) and 60 C
(1 min), ending with a melting curve analysis to control for
ampliﬁcation. All reactions were performed in triplicate and the
mean cycle threshold was used for analysis. The mRNA levels of
target genes were normalized to the house-keeping gene TATA
binding protein (TBP) using the 2Dct method. Primer sequences are
available upon request.
2.7. Analysis of plasma CORT using enzyme-linked immunosorbent
assay (ELISA)
Trunk blood was collected at time of sacriﬁce, which occurred
between 8 and 10 am for all experiments. Blood was stored in
0.5mL heparin and centrifuged at 3000 rpm for 20min. Plasmawas
removed and stored frozen (80 C) until analysis. The amount of
CORT in the plasma from each sample was measured in duplicate
by ELISA following the manufactures instructions (Immunodiag-
nostic Systems, Fountain Hills, AZ). Intra-assay variability for the
CORT kit ranged from 5.9% to 7.0%, inter-assay variability ranged
from 8.2 to 8.9%; mean assay sensitivity was 0.17 ng/mL.
2.8. Data analysis
One-way and two-way ANOVA were performed to examine the
signiﬁcance of differences between treatments. Signiﬁcant overall
main effects (p < 0.05) or interactions showing a trend (p < 0.10)
were followed by Tukey or Bonferroni post-hoc tests. For all follow-
up tests, p < 0.05 was considered statistically signiﬁcant. Data are
expressed as mean ± SEM.
3. Results
3.1. The effects of 10 mg CORT pellet exposure and ﬂuoxetine
treatment on behavior
Mice were randomly assigned to either placebo or CORT pellet
exposure, and then further separated into either saline or ﬂuoxe-
tine treatment groups. As seen in Fig. 1A, a two-way repeated
measures ANOVA revealed a signiﬁcant interaction
[F(9,102) ¼ 3.761, p < 0.001] and main effect [F(3,102) ¼ 12.68,
p < 0.001] of time on body weight during drug treatment. Placebo-
treated animals exhibited signiﬁcant weight gain by day 14
(p < 0.05). Although CORT-exposed animals failed to gain weight
within the initial 7 days of treatment, animals subsequently treated
with ﬂuoxetine showed signiﬁcant weight gain by day 21
(p < 0.001) whereas saline treated animals continued to show
inhibited weight gain. The overall change in body weight (from day
1 to day 21) shown in Fig. 1B illustrates a signiﬁcant main effect of
treatment with ﬂuoxetine [F(1, 34) ¼ 8.830, p < 0.01].
The behavioral effects of CORT and ﬂuoxetine treatment were
then measured in the NIH test. Exposure to a novel environment
increased approach latency [F(1,65) ¼ 972.4, p < 0.0001] and
Fig. 1. Effects of 10 mg CORT pellet and ﬂuoxetine treatment on weight gain. SAL ¼
Saline, FLX ¼ Fluoxetine, CORT ¼ Corticosterone. Arrow denotes start of ﬂuoxetine
treatment. (A) Weight change over time in each treatment group. Placebo treated
animals gained weight over time. CORT/SAL animals displayed inhibited weight gain
whereas CORT/FLX animals showed normal weight gain after beginning FLX treatment.
Symbols represent signiﬁcant differences compared to day 1: a (PLACEBO/FLX,
p < 0.05) b (PLACEBO/SAL, p < 0.01) c (CORT/FLX, p < 0.01) (B) Overall weight change
(from day 1 to day 21) showed that ﬂuoxetine treatment increased weight gain in both
placebo and CORT treated animals (n ¼ 9e10 per group). Data is depicted as
mean ± SEM. ##p < 0.01 within placebo or CORT treated groups.
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compared to home cage in all treatment groups. There was a sig-
niﬁcant interaction between CORT exposure and ﬂuoxetine treat-
ment in approach latencies in the novel environment
[F(1,33) ¼ 8.041, p < 0.01]. CORT-exposed animals treated with
ﬂuoxetine displayed signiﬁcantly lower approach latencies
compared to CORT-exposed animals treated with saline. Moreover,
ﬂuoxetine treatment had no effect on approach latency in placebo-
treated animals in the novel environment (Fig. 2A). There were no
signiﬁcant differences in food consumption in the novel environ-
ment between drug treatment groups (Fig. 2B). In the home cage,
CORT treatment signiﬁcantly reduced latency to approach [F(1,
33) ¼ 4.772, p < 0.05] and increased the amount of food consumed
compared to placebo treated animals [F(1, 34) ¼ 4.956, p < 0.05]
(Fig. 2C and D).
3.2. The effects of 10 mg CORT pellet exposure and ﬂuoxetine
treatment on hippocampal cell proliferation, CORT plasma levels and
corticosteroid receptor expression
In a separate cohort, animals received a single injection of BrdU
on the last day of drug treatment and were sacriﬁced 24 h later.
Hippocampal tissue was analyzed for BrdU positive cells and
corticosteroid mRNA expression. Additionally, trunk blood was
collected at time of sacriﬁce and analyzed for plasma CORT levels.
As seen in Fig. 3A, ﬂow cytometric analysis of hippocampal tissue
revealed that in placebo treated animals, ﬂuoxetine had no effect onhippocampal cell proliferation. Interestingly, CORT-exposure
signiﬁcantly increased hippocampal cell proliferation compared
to placebo treated animals [F(1,59) ¼ 50.87, p < 0.001]. Moreover,
there was a signiﬁcant interaction between CORT exposure and
ﬂuoxetine treatment on neurogenesis [F(1, 59) ¼ 6.702, p < 0.05].
Post-hoc multiple comparisons revealed that CORT-exposed ani-
mals treated with ﬂuoxetine displayed signiﬁcantly higher hippo-
campal cell proliferation compared to CORT-exposed animals
treated with saline.
Analysis of circulating CORT levels at the time of sacriﬁce
revealed that exposure to CORT pellets signiﬁcantly reduced CORT
plasma levels in both saline and ﬂuoxetine treated animals by
approximately 50% when measured on day 21 [F(1, 66) ¼ 36.06,
p < 0.001] (Fig. 3B). Fluoxetine treatment did not alter CORT levels.
Glucocorticoid (GR) and mineralocorticoid (MR) receptor tran-
scription was examined in the hippocampus as a potential molec-
ular mechanism underlying the CORT-induced neurogenic
response to ﬂuoxetine in C57BL/6 mice. There was no signiﬁcant
effect of CORT or ﬂuoxetine on GR mRNA expression (Fig. 3C).
However, exposure to CORT signiﬁcantly reduced hippocampal MR
mRNA expression in both saline and ﬂuoxetine treated animals
[F(1,68) ¼ 4.276, p < 0.05] (Fig. 3D).
3.3. The effects of adrenalectomy on 10 mg CORT pellet exposure
induced hippocampal cell proliferation
To investigate the mechanisms underlying the increase in hip-
pocampal cell proliferation by CORT pellets, adrenalectomized an-
imals were used to examine the effects of 10 mg CORT pellet
exposure and ﬂuoxetine treatment on hippocampal neurogenesis
in the absence of adrenal feedback. There was a signiﬁcant main
effect of CORT on cell proliferation [F(1, 30) ¼ 5.298, p < 0.05] and a
trend towards an interaction [F (1, 30) ¼ 3.372 p ¼ 0.08]. As illus-
trated in Fig. 4A, adrenalectomized CORT-exposed animals treated
with ﬂuoxetine, but not saline, displayed a signiﬁcant two-fold
increase in cell proliferation compared to placebo treated animals
(p < 0.05). However, CORT treatment did not increase cell prolif-
eration in adrenalectomized animals.
3.4. The effects of 2.5 mg CORT pellet exposure and ﬂuoxetine
treatment on hippocampal cell proliferation
We next examined whether a lower dose of CORT pellet expo-
sure combined with ﬂuoxetine treatment would induce an increase
in hippocampal neurogenesis in intact animals. There was a sig-
niﬁcant main effect of CORT pellet exposure [F(1, 35) ¼ 6.477,
p < 0.05] and a signiﬁcant interaction between CORT pellet expo-
sure and ﬂuoxetine treatment [F(1, 35) ¼ 4.705, p < 0.05] on hip-
pocampal cell proliferation. As shown in Fig. 4B, CORT-exposed
animals treated with saline exhibited a signiﬁcant increase in cell
proliferation compared to placebo treated animals, as in prior
studies. In contrast, the lower dose of CORT pellet was incapable of
increasing hippocampal cell proliferation when combined with
ﬂuoxetine treatment.
3.5. Evaluation of the sustained effects of 10 mg CORT pellet
treatment on plasma CORT levels
To determine whether 10 mg CORT pellets maintain elevated
plasma CORT levels for the advertised duration, adrenalectomized
animals were implanted with 10 mg CORT pellets on day 0 and,
CORT plasma levels were assessed on day 1, 7, 14, and 21 post-
implantation. As shown in Fig. 5, plasma CORT levels changed
dramatically over time (F(3,19) ¼ 16.18, p < 0.01), and were no
longer in the supraphysiological range by the seventh day of CORT
Fig. 2. Effects of 10 mg CORT pellet and ﬂuoxetine treatment in the novelty induced hypophagia test. SAL ¼ Saline, FLX ¼ Fluoxetine, CORT ¼ Corticosterone. A) Fluoxetine
signiﬁcantly reduced approach latency in the novel arena in animals exposed to CORT, but not placebo. B) There was no effect of treatment on amount consumed. C) In the home
cage, CORT exposure signiﬁcantly reduced latency to approach and D) increased the amount of food consumed (n ¼ 8e10 per group). Data is depicted as mean ± SEM. #p < 0.05
within CORT treated groups, *p < 0.05 between placebo and CORT treated groups.
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Activation of stress circuitry from implanted CORT pellets pro-
duced behavioral and neurogenic effects from chronic ﬂuoxetine
treatment in a strain of mice that would otherwise have been un-
responsive to the effects of the antidepressant. Speciﬁcally, co-
treatment of CORT with ﬂuoxetine signiﬁcantly reduced the ef-
fects of novelty stress measured on approach behavior in the NIH
test and increased hippocampal cell proliferation. These two effects
of antidepressant treatment have been linked together because the
behavioral response to ﬂuoxetine is blocked in mice that cannot
increase hippocampal cell proliferation (Sahay and Hen, 2007).
Although treatment with CORT alone unexpectedly increased cell
proliferation to a lesser extent, this effect was absent in adrenal-
ectomized mice while the augmented combination treatment ef-
fect was preserved. Measurement of plasma CORT levels revealed
that the CORT pellet did not maintain elevated levels for more than
a few days, even though it was expected to be active for 21 days,
suggesting that the impact of the CORT treatment was likely the
after-effect resulting from the supraphysiological levels of acute
exposure. Overall, these ﬁndings reveal potential neurobiological
mechanisms underlying effective antidepressant response in a
unique model of treatment resistance.
Hyponeophagia, the unconditioned suppression of feeding in a
novel environment, is a behavioral measure of stress that may be
sensitive to the anxiolytic effects of chronic, but not acute, anti-
depressant treatment with SSRIs (Bechtholt et al., 2007; Bodnoffet al., 1988; Bodnoff et al., 1989; Dulawa and Hen, 2005; Dulawa
et al., 2004). Fluoxetine's effect of reducing approach latency to
food in a novel environment is abolished after focal irradiation of
the hippocampus or genetic deletion of hippocampal precursor
cells, indicating that hippocampal neurogenesis is a necessary
component of this behavioral antidepressant response (David et al.,
2009; Santarelli et al., 2003; Surget et al., 2008; Wang et al., 2008).
Intriguingly, unlike other mouse strains, C57BL/6 mice did not
exhibit reduced hyponeophagia or increased hippocampal neuro-
genesis following chronic ﬂuoxetine treatment (Balu et al., 2009a).
However, in the present study, we showed that CORT-exposure via
pellet implantation induced a behavioral response to ﬂuoxetine in
the NIH test in this unresponsive strain. Moreover, CORT-exposure
in combination with ﬂuoxetine treatment produced a robust in-
crease in hippocampal neurogenesis that was not seen in placebo
treated animals. Although correlative, the increased behavioral
response to chronic ﬂuoxetine treatment in CORT-treated mice
could be attributed to heightened hippocampal cell proliferation.
Stress is a well-established robust inhibitor of adult neuro-
genesis (Gould and Tanapat, 1999; McEwen et al., 2012). Similarly,
CORT exposure alone has been shown to be a negative regulator of
hippocampal neurogenesis (Bilsland et al., 2006; Brummelte and
Galea, 2010; Cameron and Gould, 1994; Murray et al., 2008;
Wong and Herbert, 2004). Reduced hippocampal cell proliferation
typically coincides with increased plasma CORT levels, signifying
that circulating CORT levels at the time of testing underlie CORT-
induced changes in proliferation (Wong and Herbert, 2006). Para-
doxically, we observed dramatically reduced plasma CORT levels in
all CORT-exposed animals following the 21-day pellet treatment,
Fig. 3. Effects of 10 mg CORT pellet and ﬂuoxetine treatment on hippocampal cell proliferation, CORT plasma levels, and hippocampal corticosteroid receptor expression. SAL ¼
Saline, FLX ¼ Fluoxetine, CORT ¼ Corticosterone. A) Values are expressed as the number of BrdU-positive cells per 10,000 7-AAD events. Intact animals exhibited a signiﬁcant
increase in hippocampal cell proliferation after treatment with CORT. This effect was further augmented in CORT-exposed animals treated with ﬂuoxetine. Fluoxetine had no effect
in placebo treated animals (n ¼ 14e18 per group). B) CORT treatment signiﬁcantly reduced plasma CORT levels. Fluoxetine had no additive effect on CORT levels (n ¼ 15e19 per
group). C) CORT had no effect on hippocampal GR mRNA expression but (D) reduced hippocampal MR mRNA expression (n ¼ 15e19 per group). Data is depicted as mean ± SEM.
###p < 0.001 within CORT treated groups, ***p < 0.001, *p < 0.05 between placebo and CORT treated groups.
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this might have been due to unanticipated changes in adrenal
function. The adrenals operate through an inhibitory feedback
system in which increased circulating CORT levels serve as a signal
for reduced synthesis and secretion from the adrenals (Herman and
Cullinan, 1997; Sapolsky et al., 1984). CORT pellet treatment may
have increased internal negative feedback to the point of adrenal
inactivation, resulting in reduced endogenous circulating CORT
levels and disinhibition of cell proliferation. To test for this we
examined the effects of CORT pellet and chronic ﬂuoxetine co-
treatment on hippocampal cell proliferation in adrenalectomized
animals. Notably, in the absence of adrenal feedback, CORT-exposed
animals treated with saline did not demonstrate increased neuro-
genesis whereas those given ﬂuoxetine still exhibited a prolifera-
tive response. Therefore, the mechanisms underlying the
augmented neurogenic effect seen in combination treated animals
cannot be attributed to artifacts of adrenal feedback. It is important
to note, however, that adrenalectomized animals in all treatment
groups were supplemented with a low dose CORT-treatment
(25 mg/ml) delivered via drinking water. This mode of delivery
produces small rhythmic changes in plasma CORT levels, which
have been shown to be necessary for ﬂuoxetine-stimulated neu-
rogenesis in rats (Huang and Herbert, 2006). It is possible, then,
that rhythmic ﬂuctuations in CORT levels modulate sensitivity to
the proliferative effects of ﬂuoxetine. In spite of this, adrenalecto-
mized placebo animals treated with ﬂuoxetine did not exhibit
increased proliferation, demonstrating that supplemental CORT
alone was not sufﬁcient to induce a neurogenic response toﬂuoxetine.
To determine whether a lower dose of CORT could elicit a
neurogenic response in the presence of ﬂuoxetine without
increasing proliferation on its own, we evaluated hippocampal cell
proliferation in intact animals treated with 2.5 mg CORT pellets.
Similar to the 10 mg CORT pellet treatment, exposure to 2.5 mg
CORT pellet treatment produced elevated cell proliferation. How-
ever, there was no additional effect in the presence of ﬂuoxetine,
suggesting that this dose is sufﬁcient to produce CORT-induced
increases in neurogenesis, but not sufﬁcient to elicit an
augmented proliferative response when combined with ﬂuoxetine.
This ﬁnding is in contrast to David et al. (2009) who showed a low
dose of 5 mg/kg/day CORT treatment to be effective in reducing
hippocampal cell proliferation alone and stimulating proliferation
when paired with ﬂuoxetine treatment in C57BL/6 mice. However,
whereas the current study utilized a three-week CORT pellet
treatment, David and colleagues had CORT delivered though
drinking water and animals were treated for a substantially longer
period of time (7 weeks). Therefore, rhythmic low dose CORT
treatment over a longer period of timemay be sufﬁcient to increase
neuronal sensitization to ﬂuoxetine in this strain.
Hippocampal MRs and GRs play a vital role in mediating stress
responsiveness. Altered corticosteroid activity can dysregulate the
stress response system and enhance the risk of development of
stress-related disorders (Groeneweg et al., 2012). On the other
hand, synergistic interactions between hippocampal corticosteroid
receptors and serotonergic signaling pathways may mediate the
effects of CORT exposure on enhancing the neurogenic responses to
Fig. 4. Effects of adrenalectomy or low dose CORT exposure on hippocampal cell
proliferation. SAL ¼ Saline, FLX ¼ Fluoxetine, CORT ¼ Corticosterone. A) Values are
expressed as the number of BrdU-positive cells per 10,000 7-AAD events. In adrenal-
ectomized animals exposed to 10 mg CORT pellets, ﬂuoxetine produced an increase in
proliferation (n ¼ 7e9 per group. B). In intact animals exposed to 2.5 mg CORT pellets,
hippocampal cell proliferation was increased, but not further augmented by ﬂuoxetine
(n ¼ 9e10 per group). Data is depicted as mean ± SEM. #p < 0.05 within CORT treated
groups, *p < 0.05 between placebo and CORT treated groups.
Fig. 5. Effects of CORT pellet on plasma CORT levels over time. Adrenalectomized
animals implanted with 10 mg CORT pellets displayed signiﬁcantly reduced CORT
plasma levels after 7 days of treatment (n ¼ 5e6 per group). Data is depicted as
mean ± SEM. Absolute mean values are: 247.2 ± 43.92, 20.8 ± 7.02, 34.7 ± 24.44 and
37.6 ± 16.32 ng/ml ****p < 0.0001, ***p < 0.001 compared to day 1.
S.A. Robinson et al. / Neurobiology of Stress 3 (2016) 34e4240ﬂuoxetine in C57BL/6 mice. For example, CORT treatment has been
shown to facilitate ﬂuoxetine-induced enhancement of dopami-
nergic modulation at the mossy ﬁber synapse (Kobayashi et al.,
2013).
Consistent with recent ﬁndings, CORT treatment reducedhippocampal MR mRNA expression while having no effect on GR
mRNA expression (Saenz del Burgo et al., 2013), suggesting that MR
mRNA expression is more sensitive to the effects of CORT exposure.
This may be due to the fact that MRs exhibit 10-fold higher afﬁnity
for CORT compared to GRs (Joels et al., 2008). Hippocampal MRs
selectively contribute to neuronal stability and excitatory tone and
have been shown to mediate behavioral reactivity to a novel
environment (Berger et al., 2006; Oitzl et al., 1994), hence changes
in MR expression and function are likely to impact both hippo-
campal plasticity and associated behaviors. Interestingly, in the
current study, MR expression was similar between CORT-exposed
animals treated to either saline or ﬂuoxetine treated, indicating
that variations in expression alone cannot explain the augmented
behavioral and neurogenic responses seen in CORT-exposed ani-
mals treated with ﬂuoxetine. However, it is important to note that
MR and GR expression exhibit a diurnal regulation that is modu-
lated by circulating CORT levels (Herman et al., 1993; Holmes et al.,
1995). Since exogenous CORT treatment has been reported to
ﬂatten the natural circadian rhythm of plasma CORT (Leitch et al.,
2003), CORT pellet exposure could potentially alter rhythmic MR
and GR occupancy throughout the day. Thus, the observed neuro-
genic effects of CORT and ﬂuoxetine treatment might be mediated
by changes in circadian expression of MR and GRs. Further studies
are needed to conﬁrm this.
A major caveat of this study is the lack of sustained CORT release
from the pellet treatment. CORT pellets have been used to model
chronically elevated CORT levels, a physiological indicator of dys-
regulated HPA axis functioning and risk factor for the onset of MDD
(Goodyer et al., 2010; Owens et al., 2014). On the contrary, we found
that CORT plasma levels dropped precipitously between day 1 and
day 7 of CORT pellet treatment. Rather than a sustained release, the
CORT pellets produced a rapid, but short-lived, elevation of CORT
during the initial days of exposure and then became inactive,
resulting in CORT levels falling to the normal physiological range at
the time of the experimental studies. Similar ﬁndings were re-
ported in another study evaluating the performance of pellets
designed to release CORT for 7 days in birds. Muller et al.
(2009) found that CORT plasma levels peaked 1e2 days after pel-
let implantation and reached placebo levels by day 3. The authors
posited that the pellets, being originally designed for rodents, are
not as effectively metabolized in other species. However, our data
corroborate the ﬁndings that the CORT pellets do not reliably
produce sustained CORT release for the indicated length of treat-
ment. In light of this, slow-release CORT pellets are not appropriate
for modeling prolonged elevated CORT levels. Instead, these pellets
may more closely model the effects of exposure to a strong acute
stressor, as with post-traumatic stress disorder. Interestingly, the
initial surge in CORT levels during the ﬁrst few days of treatment
was sufﬁcient to induce long lasting molecular and behavioral
changes in treated animals, suggesting that alterations in CORT
levels, not necessarily at a pathological level, can impact the efﬁ-
cacy of ﬂuoxetine.
In conclusion, this study found that exposure to exogenous
CORT increases behavioral and neurogenic sensitivity to chronic
ﬂuoxetine treatment in C57BL/6 mice, a typically non-responsive
strain of mice. These data recapitulate the general ﬁndings that
genetic background and environment play a fundamental role in
antidepressant response. Although slow-release CORT pellets did
not model the effects of sustained elevated CORT exposure as
anticipated, these studies effectively indicate that CORT exposure is
sufﬁcient to reveal the anxiolytic and neuroplastic effects of chronic
ﬂuoxetine treatment in a typically unresponsive strain and could
model an augmentation strategy for treatment-resistant patients.
These ﬁndings implicate corticosteroid receptor activity and mod-
ulation as a potential variable in the stratiﬁcation of antidepressant
S.A. Robinson et al. / Neurobiology of Stress 3 (2016) 34e42 41response in patients with MDD and possibly as a mediator of the
effects of environmental stress on the effects of antidepressants.
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